Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
09 Gennaio 2025 - 2:44PM
Business Wire
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), today
announced that Chairman and Chief Executive Officer, Quang X. Pham,
will participate in a webcasted fireside chat at the Lytham
Partners 2025 Investor Healthcare Summit, taking place virtually on
Monday, January 13, 2025.
Cadrenal Therapeutics is a biopharmaceutical company focused on
developing tecarfarin, a novel oral vitamin K antagonist (VKA) in
advanced clinical development and designed to be a superior and
safer chronic anticoagulant therapeutic for warfarin-dependent
patients with implanted cardiac devices or rare cardiovascular
conditions.
The fireside chat will take place at 10:30 a.m. Eastern time on
Monday, January 13, 2025. The webcast can be accessed by visiting
the conference home page at https://lythampartners.com/health2025/
or directly at https://lythampartners.com/health2025/cvkd. A replay
of the fireside chat will also be available through same links.
1x1 investor meetings will be available after the event upon
request by contacting your Lytham representative at
1x1@lythampartners.com.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics, Inc. is a biopharmaceutical company in
advanced clinical development focused on developing tecarfarin, a
novel oral and reversible anticoagulant for the prevention of heart
attacks, strokes, and deaths due to blood clots in patients with
rare cardiovascular conditions.
Tecarfarin is a vitamin K antagonist (VKA) potentially
representing the first new therapeutic innovation in 70 years in
VKA anticoagulation. Tecarfarin is designed to be a superior and
safer chronic oral anticoagulant therapy compared to warfarin for
patients with implanted cardiac devices or rare cardiovascular
conditions.
Cadrenal Therapeutics’ drug candidate, tecarfarin, is expected
to enter its pivotal Phase 3 trial during 2025. The Company’s
clinical program for tecarfarin is supported by extensive data
demonstrating the molecule’s potential as an alternative to
warfarin, with safety data indicating fewer adverse events such as
strokes, heart attacks, bleeds, and deaths in comparison with
warfarin. The FDA granted tecarfarin orphan drug designation (ODD)
for heart failure patients with implanted left ventricular assist
devices (LVADs) as well as both ODD and Fast Track designation for
end-stage kidney disease (ESKD) patients with atrial fibrillation
(AFib).
For more information, please visit www.cadrenal.com and connect
with the company on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250109166162/en/
Corporate and Investor Relations Lisa DeScenza
LaVoieHealthScience (978) 395-5970
ldescenza@lavoiehealthscience.com Media Andrew Korda
LaVoieHealthScience (617) 865-0043
akorda@lavoiehealthscience.com
Grafico Azioni Cadrenal Therapeutics (NASDAQ:CVKD)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Cadrenal Therapeutics (NASDAQ:CVKD)
Storico
Da Gen 2024 a Gen 2025
